3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urinary Bladder Neoplasms
12
Carcinoma, Transitional Cell
7
Ureteral Neoplasms
4
Neoplasm Metastasis
3
Urethral Neoplasms
2
Urothelial Cancer
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Renal Insufficiency
1
Prostatic Neoplasms
1
Penile Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Kidney Neoplasms
1
Carcinoma
1
Interventions
Gemcitabine
24
Cisplatin
18
Carboplatin
10
Paclitaxel
9
Specimen Handling
6
Nivolumab
6
Doxorubicin
6
Docetaxel
6
pembrolizumab
5
Magnetic Resonance Spectroscopy
5
cabozantinib
4
avelumab
4
Vinblastine
4
Radiotherapy
4
Methotrexate
4
Fluorouracil
4
enfortumab vedotin
3
atezolizumab
3
aflibercept
3
Trastuzumab
3
Sunitinib
3
Ramucirumab
3
Platinum
3
Ipilimumab
3
CTLA-4 Antigen
3
Biopsy
3
1,2-diaminocyclohexaneplatinum II citrate
3
vinflunine
2
pegfilgrastim
2
Sorafenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Urethral Neoplasms
×
vinflunine
×
Genitourinary
×
Clear all
NCT02665039
2019-10-08
VINGEM
Karolinska University Hospital
Phase 2
Completed
62 enrolled
NCT01844947
2019-04-26
VINSOR
Karolinska University Hospital
Phase 1
Completed
22 enrolled